A Single-center, Randomized, Investigator/Subject-Blind, Adaptive Single-ascending Dose (Part 1) and Multiple Ascending Dose (Part 2), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6889450 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs RO 6889450 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 21 Nov 2017 Status changed from recruiting to completed.
- 01 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
- 01 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.